S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
NFLX   293.35 (+2.47%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
NFLX   293.35 (+2.47%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Akari Therapeutics Stock Price, News & Analysis (NASDAQ:AKTX)

$1.73
-0.04 (-2.26 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$1.73
Now: $1.73
$1.78
50-Day Range
$1.63
MA: $1.88
$2.12
52-Week Range
$1.56
Now: $1.73
$9.20
Volume4,757 shs
Average Volume305,540 shs
Market Capitalization$27.44 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.9
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKTX
CUSIPN/A
Phone646-350-0702

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.20 per share

Profitability

Net Income$-16,470,000.00

Miscellaneous

Employees17
Market Cap$27.44 million
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable

Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.


Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics PLC (NASDAQ:AKTX) announced its earnings results on Thursday, August, 29th. The biopharmaceutical company reported ($0.26) EPS for the quarter. View Akari Therapeutics' Earnings History.

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 21st 2019. View Earnings Estimates for Akari Therapeutics.

What price target have analysts set for AKTX?

1 brokerages have issued 1 year price objectives for Akari Therapeutics' stock. Their forecasts range from $7.00 to $7.00. On average, they expect Akari Therapeutics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 304.6% from the stock's current price. View Analyst Price Targets for Akari Therapeutics.

What is the consensus analysts' recommendation for Akari Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akari Therapeutics.

Has Akari Therapeutics been receiving favorable news coverage?

Media coverage about AKTX stock has trended negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Akari Therapeutics earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Akari Therapeutics.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 583,000 shares, an increase of 176.8% from the August 30th total of 210,600 shares. Based on an average trading volume of 1,090,000 shares, the short-interest ratio is currently 0.5 days. Currently, 3.3% of the company's stock are sold short. View Akari Therapeutics' Current Options Chain.

Who are some of Akari Therapeutics' key competitors?

What other stocks do shareholders of Akari Therapeutics own?

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the folowing people:
  • Dr. Ray Prudo, Exec. Chairman (Age 74)
  • Mr. Clive Richardson, COO, Director & Interim CEO (Age 54)
  • Mr. Dov Elefant, Chief Financial Officer (Age 52)
  • Dr. Miles Nunn, Chief Scientific Officer

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.73.

How big of a company is Akari Therapeutics?

Akari Therapeutics has a market capitalization of $27.44 million. The biopharmaceutical company earns $-16,470,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Akari Therapeutics employs 17 workers across the globe.View Additional Information About Akari Therapeutics.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is http://www.akaritx.com/.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 646-350-0702 or via email at [email protected]


MarketBeat Community Rating for Akari Therapeutics (NASDAQ AKTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics and other stocks. Vote "Outperform" if you believe AKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel